Cancer blocking agents

Patel, J. B., J. Mehta et al. (2007). Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br. J. Cancer 96(8) 1204—1215. 

Serious life-threatening infections, including sepsis and pneumonia, have been reported with the use of TNF inhibitors. Patients should be evaluated for tuberculosisrisk factors and tested for latent tuberculosis infection prior to starting therapy. Concurrent use with other immunosuppressive therapy should be avoided. In clinical trials of all TNF-blocking agents more cases of lymphoma were observed compared with control patients. Patients with a prior history of prolonged phototherapy treatment should be monitored for nonmelanoma skin cancers. 

The studied molecules include such diverse compounds as volatile anesthetics (halothane), local anesthetics of the cocaine type, calcium channel-blocking agents such as verapamil, antidepressants (chlorpromazine), and anti cancer drugs such as adriamycin. It is argued that the factor of interest to the physiological effect may not... 

In the controlled portions of clinical trials of some TNF-blocking agents including Remicade, more malignancies (excluding lymphoma and nonmelanoma skin cancers) have been observed in patients receiving the TNF-blocker compared with control patients... 

Nucleotide biosynthetic pathways are tremendously important as intervention points for therapeutic agents. Many of the most widely used drugs in the treatment of cancer block steps in nucleotide biosynthesis, particularly steps in the synthesis ofDNA precursors. 

Braun S, Boyko V, Behar S, Reicher-Reiss H, Laniado S, Kaplinsky E, Goldbourt U. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group. J Am Coll Cardiol 1998 31(4) 804-8. 

The nausea and vomiting associated with circulating physical agents (radiation therapy and virus particles) and chemical agents (toxins and cancer chemotherapeutic agents) are treated with phenothiazine derivatives such as chlorpromazine, perphenazine, prochlorperazine, promethazine, triethylperazine, and triflupromazine. These agents block the dopamine receptors in the area postrema (see Figure 73). 

---